Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Roberto Russo 1,2,†, Niccolò Capurro 1,2,†, Emanuele Cozzani 1,2 and Aurora Parodi 1,2,*

1 Department of Health Science (DISSAL), University of Genoa, 16132 Genoa, Italy; russoroberto@outlook.com (R.R.); capurro.niccolo@gmail.com (N.C.); emanuele.cozzani@unige.it (E.C.)
2 Unit of Dermatology, San Martino Polyclinic Hospital, 16132 Genoa, Italy
* Correspondence: aurora.parodi@unige.it
† These authors contributed equally to this work.

Abstract: Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal bullous disease. At present, the main treatment options are represented by corticosteroids and immunosuppressant drugs. Steroids often need to be administered in high doses, with subsequent adverse events and safety issues, as BP mainly affects elderly people. As dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα has become paramount in the treatment of atopic dermatitis, its use in autoimmune bullous diseases has been theorized and it has been used to treat patients with BP. Dupilumab seems to be an effective and safe option to treat recalcitrant BP. Here, we report the results of a literature review on the use of dupilumab in BP, including a total of 30 treated patients in 9 papers.

Keywords: bullous pemphigoid; dupilumab; autoimmune blistering diseases

Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal bullous disease. At present, the main treatment options are represented by corticosteroids and immunosuppressant drugs. Steroids often need to be administered in high doses, with subsequent adverse events and safety issues, as BP mainly affects elderly people. In fact, overall mortality is significantly increased in BP, owing to both comorbidities and iatrogenic immunosuppression. Therefore, novel effective treatment options with fewer safety concerns are a matter of ongoing research [1].

As dupilumab, a recombinant fully human IgG4 monoclonal antibody with binding specificity to human interleukin-4 receptor IL-4Rα, has become paramount in the treatment of atopic dermatitis, and its use in autoimmune bullous diseases was theorized in 2019 [2]. In fact, dupilumab has been demonstrated to modulate chemokine-ligand 18, IL-4 and IL-13. These are Th2-related cytokines that show higher levels in BP patients (both in sera and in blister fluid) and play a role in the maintenance of Th2-type responses, which are thought to be involved in the loss of tolerance against BP180 [2]. From then on, reports of use of dupilumab in BP have been published. We performed research via the PubMed, Google Scholar, and clinicaltrials.gov databases using the search terms “dupilumab” and “pemphigoid”.

The first case report actually dates back to 2018: a patient with BP refractory to prednisone was successfully treated with dupilumab [3]. Later, Seidman et al. as well as Saleh et al. described patients with intractable BP who failed to respond to many different therapies but reached stable improvement when treated with dupilumab, understanding “improvement” symptoms as pruritus and blistering becoming well-controlled [4,5]. Abdat et al. published the first multicentric case series: of 13 patients, 9 achieved complete clinical response, where “satisfactory response” was defined by the authors as a “documented clinical improvement and patient desire to continue dupilumab.” In no more than 4 months, three showed partial response and only one
patient failed to respond [6]. Additionally, a case of nivolumab-induced BP successfully treated with dupilumab has been reported [7]. Unfortunately, it was not clarified if nivolumab needed to be discontinued; if not, dupilumab would represent a safe and effective treatment to allow oncologic patients to continue nivolumab, even in the event of drug-induced BP. Zhang et al. retrospectively compared 8 BP patients treated with dupilumab plus azathioprine or methylprednisolone to 16 conventionally treated patients. Adding dupilumab resulted in the better control of disease progression and accelerated the tapering of glucocorticoids, while no adverse event related to dupilumab were recorded [8]. Liu et al. reported three patients with recalcitrant BP who significantly improved after treatment with dupilumab [9]. More recently, a very interesting report by Shan et al. described the case of a patient with vesicular BP concurrent with pulmonary tuberculosis which contraindicated a prolonged immunosuppressive therapy. Treatment with dupilumab resulted in the remission of vesicular BP, while pulmonary tuberculosis stayed well controlled [10]. Dupilumab was also proposed together with omalizumab as a successful combination therapy for BP; however, it is debatable that the patient was treated with two expensive biologic agents without an evident rationale, whereas monotherapy with dupilumab was not administered in this case [11]. Takamura and Teraki presented a case of a diabetic woman whose BP promptly responded to dupilumab, and also described the decrease in the proportion of circulating IL-4- and IL-13-producing CD4+ T cells (but not CD8+ T cells) after treatment, suggesting that dupilumab may exert its effect on BP by suppressing effector Th2 cells. However, the patient from this report was on glitins, and it is unclear if they were discontinued as BP was diagnosed [12]. Table 1 summarizes the reports on use of dupilumab in BP.

A significant aspect that emerges from this review of various papers on the use of dupilumab in patients with BP as an implementing therapy is its high safety profile. In fact, several authors report the use of dupilumab in patients with multiple chronic diseases, including three cases of malignant neoplasms and one case of active tuberculosis (contraindicating other treatments), without substantial adverse events. The use of dupilumab was also shown to be optimally tolerated in patients receiving polypharmacotherapy either for previous health issues or for the treatment of BP. Two patients even took dupilumab concurrently with other biologic drugs, namely nivolumab and omalizumab, without significant interactions. Notably, none of the patients treated with dupilumab had been previously or concomitantly treated with rituximab. In almost all cases, there was clearance of disease after the use of dupilumab. Dupilumab was also effective on the side of symptoms, completely or greatly reversing pruritus in virtually all but one patient according to the reports. Dupilumab could play a relevant role not only in the management of severe pruritus, but also in the pathogenetic mechanisms of BP. In fact, in addition to circulating IgG, IgE are also recognized to be able to target BP180 and to trigger eosinophil and mast cell degranulation, and their serum levels seem to correlate with disease activity. IgE-mediated IL-4 and IL-13 production may be implicated in the upregulation of Th2 which seems to be the predominant immunological response in BP patients, suggesting Th2 cells’ involvement in the loss of tolerance against BP180 [13–15]. Indeed, Th2-related cytokines including IL-4 and IL-5 are overexpressed in BP lesional skin. Autoreactive Th2 cells are believed to play a dual role in BP: they stimulate B cells’ autoantibody production through the CD40-CD40L interplay and participate in the recruitment and activation of eosinophils, which may contribute to maintaining a Th2-type response via the production of IL-4, IL-5, and IL-13 [3,16,17].
Table 1. Reports of patients BP treated with dupilumab.

| Year of Publication | Number of Patients | Gender | Age (Years) | Patients’ Comorbidities | Concomitant Medication | Systemic BP Medication before Dupilumab (OVERALL) | Disease Duration before Dupilumab Initiation (Months) | Response to Dupilumab |
|---------------------|--------------------|--------|-------------|------------------------|------------------------|-----------------------------------------------|-----------------------------------------------|----------------------|
| Shan Y et al. [10]  | 2022               | 1 M    | 32          | Tuberculosis           | Isoniazid, rifampicin, and ethambutol | Oral corticosteroid                             | 3                                             | Disease clearance    |
| Saleh M et al. [5]  | 2021               | 1 M    | 80          | Not reported           | Not reported            | Prednisone 40 mg daily, doxycycline 100 mg twice daily, niacinamide 500 mg three times per day, mycophenolate mofetil 1000 mg twice daily | Not reported | Marked improvement after 2 weeks, followed by complete resolution |
| Klepper EM et al. [7]| 2021               | 1 F    | 79          | Melanoma               | Nivolumab, levothyroxine, hydrochlorothiazide /losartan, atorvastatin | Topical steroids, fexofenadine, dapsone        | Unknown | Clearance of pruritus and BP lesion after 4 weeks |
| Zhang Y et al. [8]  | 2021               | 8      | 64.50 median (IQR 45.5–71.75) | Cardiovascular disease (N = 3) | Not reported | Methylprednisolone (0.6 mg/kg/d) (N = 8) Azathioprine (2 mg/kg/d) (N = 8) | 2 Median (N = 8) | Cessation of new BP lesions (8 days median time); Median BPDAI activity score: 34.25 (range: 19–75) at week 0 and 3.7 (range: 0–9) at week 2; Disease clearance in 62.5% of patients |
| Liu X et al. [9]    | 2021               | 3      | 54 median (range 18) | Psychiatric Disorders (N = 1) HBV+ (N = 1) Hypertension, type 2 diabetes mellitus, stroke, arrhythmias with sustained atrial fibrillation, HBV+ (N = 1) | Not reported | Methylprednisolone 80 mg/d (N = 2) Prednisone (N = 1) IVIG (N = 2) Cyclophosphamide (N = 2) Cyclosporine (N = 2) Topical corticosteroids (N = 3) | 17 median (N = 3) | Disease clearance (N = 2); Disease progression (N = 1) |
| Year of Publication | Number of Patients | Gender | Age (Years) | Patients’ Comorbidities | Concomitant Medication | Systemic BP Medication before Dupilumab (OVERALL) | Disease Duration before Dupilumab Initiation (Months) | Response to Dupilumab |
|---------------------|--------------------|--------|-------------|-------------------------|------------------------|-----------------------------------------------|----------------------------------------------------|----------------------|
| Seyed Jafari SM et al. [11] | 2021 | 1 | M | 70 | Obesity, type 2 diabetes mellitus, hypertension | Not reported | Topical corticosteroids, Dapsone (up to 150 mg/day) Methotrexate 7.5 mg /week Mycophenolate-mofetil 2 g/d, Omalizumab | 24 | Disease clearance |
| Abdat R et al. [6] | 2020 | 13 | 8 M, 5F | 78 median (IQR 70.5–84.5) | Not reported | Not reported | None (N = 1) Prednisone (N = 3) Methotrexate (N = 1) Doxycycline (N = 1) Prednisone and Methotrexate (N = 2) Prednisolone, MTX, IVIG (N = 1) Prednisone, doxycycline, and niacinamide (N = 1) Prednisone, mycophenolate, doxycycline and niacinamide (N = 1) Rituximab, IVIG, doxycycline, nicotinamide, and azathioprine (N = 1) Prednisone, mycophenolate, rituximab, and IVIG (N = 1) | 20.8 median (N = 12) | Disease Clearance (N = 7); Improvement in pruritus and clearance of BP lesions (N = 2); Improvement in pruritus but no clearance of BP lesions (N = 1); No improvement in pruritus and clearance of BP lesions (N = 1); Improvement of pruritus and BP lesions (N = 1); No improvement in pruritus or BP lesions (N = 1) |
| Year of Publication | Number of Patients | Gender | Age (Years) | Patients’ Comorbidities | Concomitant Medication | Systemic BP Medication before Dupilumab (OVERALL) | Disease Duration before Dupilumab Initiation (Months) | Response to Dupilumab |
|---------------------|--------------------|--------|-------------|-------------------------|------------------------|---------------------------------------------------|--------------------------------------------------------|-----------------------|
| Seidman JS et al. [4] | 2019 | 1 | M | 89 | Type 2 diabetes mellitus | Metformin | Doxycycline 100 mg twice daily, nicotinamide 500 mg twice daily, mycophenolate mofetil 1000 mg twice daily (peak of 1500 mg twice daily), and prednisone 10 mg daily | 24 (including disease flares) | Improvement of pruritus after 2 weeks, complete BP lesions resolution after 7 weeks |
| Kaye A et al. [3] | 2018 | 1 | M | 80 | Mycobacterium tuberculosis and hepatitis B core laboratory positivities | Not reported | Prednisone | 0.3 | Improvement in pruritus within a week after first injection; Resolution of all blisters after 3 months |
| Takamura S and Teraki Y [12] | 2022 | 1 | F | 72 | Type 2 diabetes mellitus | Inhibitors of dipeptidyl peptidase 4 | minocycline with nicotinic acidamide | 1.5 | Resolution of pruritus in 2 weeks and blisters in 4 weeks |
For these reasons, we can hypothesize that the reduction in disease activity obtained in the cases reported so far may be related to the reduction in Th2-type responses induced by the inhibition of IL-4 and IL-13 signal transduction induced by dupilumab.

Certainly, dupilumab should not be intended as a first-choice treatment, in consideration of its high costs for healthcare systems, but as a rescue therapy for selected patients with recalcitrant BP.

Of course, randomized multicentric clinical studies are needed. If the results are confirmed, dupilumab might become another arrow in the quiver for the treatment of BP, as well as a safe option.

Author Contributions: All authors contributed to Conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing—original draft preparation, writing—review and editing, visualization, supervision, project administration. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not relevant.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are openly available (see references list).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Cozzani, E.; Marzano, A.V.; Caproni, M.; Feliciani, C.; Calzavara-Pinton, P.; Cutaneous Immunology Group of SIDeMaST. Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines. G. Ital. Dermatol. Venereol. Organo Uff. Soc. Ital. Dermatol. Sifiligr. 2018, 153, 305–315. [CrossRef] [PubMed]
2. Russo, R.; Cozzani, E.; Gasparini, G.; Parodi, A. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol. Ther. 2020, 33, e13190. [CrossRef] [PubMed]
3. Kaye, A.; Gordon, S.C.; Deverapalli, S.C.; Her, M.J.; Rosmarin, D. Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid. JAMA Dermatol. 2018, 154, 1225–1226. [CrossRef] [PubMed]
4. Seidman, J.S.; Eichenfield, D.Z.; Orme, C.M. Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol. Online J. 2019, 25, 12. [CrossRef]
5. Saleh, M.; Reedy, M.; Torok, H.; Weaver, J. Successful treatment of bullous pemphigoid with dupilumab: A case and brief review of the literature. Dermatol. Online J. 2021, 27, 7. [CrossRef]
6. Abdat, R.; Waldman, R.A.; de Bedout, V.; Czernik, A.; Mcleod, M.; King, B.; Gordon, S.; Ahmed, R.; Nichols, A.; Rothe, M.; et al. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. J. Am. Acad. Dermatol. 2020, 83, 46–52. [CrossRef] [PubMed]
7. Klepper, E.M.; Robinson, H.N. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: A case report and review of the literature. Dermatol. Online J. 2021, 27, 6. [CrossRef] [PubMed]
8. Zhang, Y.; Xu, Q.; Chen, L.; Chen, J.; Zhang, J.; Zou, Y.; Gong, T.; Ji, C. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid. Front. Immunol. 2021, 12, 738907. [CrossRef] [PubMed]
9. Liu, X.; Ma, J.; Qiu, X.; Hong, D.; Wang, L.; Shi, Z. Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: A case series of three patients. Eur. J. Dermatol. 2021, 31, 846–847. [CrossRef] [PubMed]
10. Shan, Y.; Zuo, Y.G. A successful case of vesicular pemphigoid concurrent with pulmonary tuberculosis with dupilumab. Dermatol. Ther. 2022, 35, e15330. [CrossRef] [PubMed]
11. Seyed Jafari, S.M.; Feldmeyer, L.; Bossart, S.; Simon, D.; Schlapbach, C.; Borradori, L. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Front. Immunol. 2021, 11, 611549. [CrossRef] [PubMed]
12. Takamura, S.; Teraki, Y. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines. J. Dermatol. 2022, preprint. [CrossRef]
13. Cozzani, E.; Gasparini, G.; Di Zенко, G.; Parodi, A. Immunoglobulin E and bullous pemphigoid. Eur. J. Dermatol. 2018, 28, 440–448. [CrossRef] [PubMed]
14. Maglie, R.; Hertl, M. Pharmacological advances in pemphigoid. Curr. Opin. Pharmacol. 2019, 46, 34–43. [CrossRef] [PubMed]
15. Moyle, M.; Cevikbas, F.; Harden, J.L.; Guttmann-Yassky, E. Understanding the immune landscape in atopic dermatitis: The era of biologies and emerging therapeutic approaches. Exp. Dermatol. 2019, 28, 756–768. [CrossRef] [PubMed]
16. Giomi, B.; Caproni, M.; Calzolari, A.; Bianchi, B.; Fabbri, P. Th1, Th2 and Th3 cytokines in the pathogenesis of bullous pemphigoid. *J. Dermatol. Sci.* **2002**, *30*, 116–128. [CrossRef]

17. Gounni Abdelilah, S.; Wellemans, V.; Agouli, M.; Guenounou, M.; Hamid, Q.; Beck, L.A.; Lamkhioued, B. Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines. *Clin. Immunol.* **2006**, *120*, 220–231. [CrossRef] [PubMed]